# Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma

> **NCT05940064** · PHASE2 · UNKNOWN · sponsor: **Peng Liu** · enrollment: 30 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Zanubrutinib, Polatuzumab Vedotin, Rituximab

## Key facts

- **NCT ID:** NCT05940064
- **Lead sponsor:** Peng Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-20
- **Primary completion:** 2025-07-20
- **Final completion:** 2025-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05940064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05940064, "Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05940064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*